Heal House Vitiligo Research 73 · Original Article
What do doctors actually look at and assess in vitiligo clinical care?
Assessment of vitiligo in clinical practice: a cross-sectional survey among experts
In short
We asked 31 vitiligo experts from 6 continents. The most common things they look at in consultations are whether the disease is improving or worsening, whether the patient is tolerating treatment well, whether it is currently spreading, and how widespread it is.
Clinical trials have a defined standard for what should be measured. However, in everyday clinical practice, the items each doctor looks at vary slightly. As a result, even for the same patient, assessments can differ, and management may not be consistent. Therefore, we conducted the first survey of what vitiligo experts actually look at in real-world clinical care. This represents a first step toward establishing common criteria. I participated in this international survey study as a co-investigator.
Q1 How Was the Survey Conducted and What Was Most Commonly Assessed?
We asked 31 vitiligo experts active across 6 continents, "What do you actually look at in your clinical practice?" They were shown a predefined list of 28 items, and any item that at least 7 out of 10 respondents reported looking at was categorized as a "commonly assessed item." As a result, 6 assessment domains and 21 patient characteristics fell into this category. The items most frequently selected were the trend of whether vitiligo is improving or worsening, tolerance of treatment (side effects), whether it is currently spreading, and how extensively it has spread. These are summarized in the table below.
Items most frequently assessed in clinical practice
| Commonly assessed items | In simple terms |
|---|---|
| Changes in vitiligo pattern | Trend of improving or worsening |
| Side effects of treatment | Tolerance of treatment |
| Disease activity | Whether it is currently spreading |
| Extent | How extensively it has spread |
Q2 Why Was This Survey Needed?
A list defining what should be measured in clinical trials was established in 2015. However, criteria for everyday clinical practice were lacking. Without such criteria, assessments vary from clinic to clinic, making it difficult to maintain a consistent treatment direction. This survey marks an important first step by identifying the items that experts commonly look at in clinical care. Interestingly, the items assessed in clinical practice showed both similarities and notable differences compared to the clinical trial list. Future plans include collaborating with experts, general practitioners, and patients to refine the clinical assessment criteria.
Closing remarks
From a patient's perspective, knowing that "wherever I go, my vitiligo will be evaluated using similar criteria" provides great reassurance. This study has laid the groundwork for developing such a common standard. It was meaningful to be part of this effort to align the level of clinical assessment globally.
